Press releases
- Ligand to Participate in Upcoming Investor Conferences
- Ligand Reports First Quarter 2024 Financial Results
- Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
- Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
- Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
- Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™
More ▼
Key statistics
As of last trade Ligand Pharmaceuticals Inc (LGDN:FRA) traded at 73.50, -10.37% below its 52-week high of 82.00, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 73.50 |
---|---|
High | 73.50 |
Low | 73.50 |
Bid | 73.50 |
Offer | 74.50 |
Previous close | 72.50 |
Average volume | 1.11 |
---|---|
Shares outstanding | 17.96m |
Free float | 17.55m |
P/E (TTM) | 15.55 |
Market cap | 1.46bn USD |
EPS (TTM) | 5.23 USD |
Data delayed at least 15 minutes, as of Jun 11 2024 07:34 BST.
More ▼